What is the appropriate management for a patient who ingested 0.05 mg of bromadiolone (rat poison)?

Management of Bromadiolone 0.05 mg Ingestion

For a patient who ingested 0.05 mg of bromadiolone, immediate baseline coagulation studies (PT/INR) should be obtained, followed by observation and serial monitoring of coagulation parameters for at least 48-72 hours, with vitamin K1 therapy initiated only if coagulopathy develops.

Initial Assessment and Risk Stratification

The ingested dose of 0.05 mg is relatively small compared to reported toxic cases. Published case reports document severe toxicity at doses of 8.5 mg (0.17 mg/kg) 1 and plasma levels as low as 117 ng/mL causing acute kidney injury 2. However, bromadiolone is a "superwarfarin" with prolonged effects, requiring vigilant monitoring regardless of dose.

Immediate Actions

• Obtain baseline coagulation studies: PT, INR, and aPTT immediately upon presentation
• Do NOT routinely administer activated charcoal unless ingestion occurred within 1-2 hours and patient can protect airway (general toxicology principle from 3)
• Contact poison control center (1-800-222-1222 in US) for case-specific guidance 3

Monitoring Protocol

Serial coagulation monitoring is essential because bromadiolone exhibits two-compartment elimination kinetics with an initial half-life of 3.5 days and terminal half-life of 24 days 1. Coagulopathy may not manifest for 24-72 hours post-ingestion.

Monitoring Schedule:

• Baseline: PT/INR, aPTT, CBC
• Repeat at 24 hours post-ingestion
• Repeat at 48 hours post-ingestion
• Repeat at 72 hours post-ingestion
• If all values remain normal at 72 hours, consider discharge with return precautions

Vitamin K1 Therapy Indications

Initiate vitamin K1 therapy ONLY if coagulopathy develops (INR >1.5 or PT prolonged). Prophylactic vitamin K1 is not indicated for asymptomatic patients with normal coagulation studies.

If Coagulopathy Develops:

Dosing regimen for symptomatic coagulopathy:

• Initial: Vitamin K1 10-50 mg IV slowly (over 30 minutes to avoid anaphylactoid reactions)
• Maintenance: 10-25 mg orally every 6-12 hours, adjusted based on INR response
• Duration: May require weeks to months of therapy given bromadiolone's 24-day terminal half-life 1

For Severe Coagulopathy with Bleeding:

• Fresh frozen plasma (FFP) for immediate factor replacement
• Prothrombin complex concentrate (PCC) if available
• High-dose vitamin K1: up to 50 mg IV every 6 hours 2, 4
• Continue until INR normalizes and remains stable

Critical Pitfalls to Avoid

1. Do not discharge without serial monitoring: Coagulopathy can develop days after ingestion due to delayed onset 1

2. Do not stop vitamin K1 prematurely: If coagulopathy develops, prolonged therapy (weeks to months) is typically required. Plasma bromadiolone levels <10 ng/mL correlate with normal coagulation 1

3. Monitor for rare but life-threatening complications:

   • Intracranial hemorrhage (subarachnoid hemorrhage, intracerebral hematoma) 5
   • Intra-abdominal bleeding (hemoperitoneum, GI bleeding) 6, 4
   • Acute kidney injury from severe coagulopathy 2
   • Paralytic ileus secondary to abdominal hemorrhage 6

4. Consider plasma bromadiolone level testing if available, though treatment decisions should be based primarily on coagulation parameters, not drug levels 1

Disposition

• If coagulation studies remain normal at 72 hours: Discharge with strict return precautions for any bleeding symptoms
• If any coagulopathy develops: Admit for vitamin K1 therapy and continued monitoring
• Provide written instructions to return immediately for: bleeding gums, hematuria, hematemesis, melena, severe headache, or any unusual bruising

The key principle is that supportive care and monitoring take priority over immediate antidotal therapy in the absence of demonstrated toxicity 3. This conservative approach balances the real but uncertain risk from this relatively low dose against the prolonged half-life and potential for delayed severe complications.